[go: up one dir, main page]

WO2009020189A1 - 血圧降下剤 - Google Patents

血圧降下剤 Download PDF

Info

Publication number
WO2009020189A1
WO2009020189A1 PCT/JP2008/064247 JP2008064247W WO2009020189A1 WO 2009020189 A1 WO2009020189 A1 WO 2009020189A1 JP 2008064247 W JP2008064247 W JP 2008064247W WO 2009020189 A1 WO2009020189 A1 WO 2009020189A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
trp
lys
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/064247
Other languages
English (en)
French (fr)
Inventor
Kyoichi Kagawa
Chizuko Fukuhama
Hiroaki Fujino
Junnei Hidasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MG Pharma Inc
Original Assignee
MG Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MG Pharma Inc filed Critical MG Pharma Inc
Priority to CN2008801023978A priority Critical patent/CN101815525B/zh
Priority to AU2008284709A priority patent/AU2008284709C1/en
Priority to KR1020107004549A priority patent/KR101244331B1/ko
Priority to US12/671,953 priority patent/US8394769B2/en
Priority to EP08827111.9A priority patent/EP2179740B1/en
Priority to JP2009526492A priority patent/JPWO2009020189A1/ja
Priority to CA2695666A priority patent/CA2695666C/en
Priority to HK11101428.7A priority patent/HK1147210B/xx
Publication of WO2009020189A1 publication Critical patent/WO2009020189A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

　本発明は血圧降下剤を提供する。本発明の血圧降下剤は、グロビン蛋白分解物に由来する下記(1)～(6)に示すアミノ酸配列からなるペプチドよりなる群から選択される少なくとも１種のペプチド、またはこれらのペプチドの少なくとも１種を含有するグロビン蛋白分解物を有効成分とする：(1) Val-Val-Tyr-Pro（配列番号１）、(2) Trp-Gly-Lys-Val-Asn（配列番号２）、(3) Trp-Gly-Lys-Val（配列番号３）、(4) Trp-Gly-Lys（配列番号４）、(5) Ala-Ala-Trp-Gly-Lys（配列番号５）、および(6) Phe-Glu-Ser（配列番号６）。
PCT/JP2008/064247 2007-08-07 2008-08-07 血圧降下剤 Ceased WO2009020189A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN2008801023978A CN101815525B (zh) 2007-08-07 2008-08-07 降血压剂
AU2008284709A AU2008284709C1 (en) 2007-08-07 2008-08-07 Anti-hypertensive agent
KR1020107004549A KR101244331B1 (ko) 2007-08-07 2008-08-07 혈압강하제
US12/671,953 US8394769B2 (en) 2007-08-07 2008-08-07 Anti-hypertensive agent
EP08827111.9A EP2179740B1 (en) 2007-08-07 2008-08-07 Anti-hypertensive agent
JP2009526492A JPWO2009020189A1 (ja) 2007-08-07 2008-08-07 血圧降下剤
CA2695666A CA2695666C (en) 2007-08-07 2008-08-07 Anti-hypertensive agent
HK11101428.7A HK1147210B (zh) 2007-08-07 2008-08-07 降血压剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007204929 2007-08-07
JP2007-204929 2007-08-07

Publications (1)

Publication Number Publication Date
WO2009020189A1 true WO2009020189A1 (ja) 2009-02-12

Family

ID=40341418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064247 Ceased WO2009020189A1 (ja) 2007-08-07 2008-08-07 血圧降下剤

Country Status (8)

Country Link
US (1) US8394769B2 (ja)
EP (1) EP2179740B1 (ja)
JP (4) JPWO2009020189A1 (ja)
KR (1) KR101244331B1 (ja)
CN (2) CN103251928B (ja)
AU (1) AU2008284709C1 (ja)
CA (1) CA2695666C (ja)
WO (1) WO2009020189A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19515847C1 (de) 1995-04-29 1996-07-18 Heidelberger Druckmasch Ag Steuervorrichtung für ein Numerier- und Eindruckwerk von Rotationsdruckmaschinen
WO2018001273A1 (zh) * 2016-06-30 2018-01-04 江西本草天工科技有限责任公司 肽或其盐、其制备方法、及其制备预防和/或治疗肝损伤药物的用途
CN107551258B (zh) * 2016-06-30 2021-01-05 江西本草天工科技有限责任公司 用于预防和/或治疗肝损伤的vvyp
CN108618101B (zh) * 2018-05-10 2021-11-23 华南理工大学 一种具有鲜味和增鲜作用的三肽及其衍生物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006970A1 (fr) 1988-02-02 1989-08-10 Hankyu-Kyoei Bussan Co., Ltd. Agent ameliorant le metabolisme des lipides et procede d'utilisation
JPH09255698A (ja) * 1996-03-22 1997-09-30 Hankyu Kyoei Bussan Inc 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤
JP2002080496A (ja) 2000-09-04 2002-03-19 Univ Kyoto 新規な降圧ペプチド
WO2006052031A1 (en) 2004-11-15 2006-05-18 Mg Pharma Inc. Protein hydrolysate with antidiabetic effect

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188282A (ja) * 1991-04-19 1995-07-25 Suetsuna Yoko 新規なトリペプチド、その製法およびそれを有効成分と する血圧降下剤
JP3108675B2 (ja) 1998-03-17 2000-11-13 阪急共栄物産株式会社 脂質代謝改善剤
AU2001281464A1 (en) * 2000-03-13 2001-09-24 Monsanto Technology Llc Recombinant proteins containing repeating units
DE10133576A1 (de) * 2001-07-13 2003-01-30 Martin Klingmueller Verwendung von physiologisch aktiven Oligopeptiden zur Stabilisierung des Immunsystems
CA2505558C (en) * 2002-11-09 2013-07-02 Avidex Limited T cell receptor display
JP2004175680A (ja) * 2002-11-25 2004-06-24 Marine Bio Kk 生体バランス改善効果を備えたミネラル含有組成物
JP2005046083A (ja) * 2003-07-30 2005-02-24 Morinaga & Co Ltd グロビン蛋白分解物含有飲料及びその製造方法
US20080063781A1 (en) * 2004-09-30 2008-03-13 Suntory Limited Globin Digest Containing, Yeast-Fermented Beverages
JP2006180840A (ja) * 2004-12-28 2006-07-13 Hiroshima Pref Gov 血栓の溶解を亢進させるポリペプチド及びその利用
JP4395658B2 (ja) * 2005-11-17 2010-01-13 エムジーファーマ株式会社 コレステロール再上昇抑制用組成物およびその用法
CN1990875A (zh) * 2005-12-30 2007-07-04 中国科学院大连化学物理研究所 一种珠蛋白酶解物及其制备和应用
CN1994464B (zh) * 2005-12-31 2010-05-05 中国科学院大连化学物理研究所 一种血管紧张素i转换酶抑制剂及其应用
JP5041780B2 (ja) * 2006-10-23 2012-10-03 エムジーファーマ株式会社 肝障害改善組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006970A1 (fr) 1988-02-02 1989-08-10 Hankyu-Kyoei Bussan Co., Ltd. Agent ameliorant le metabolisme des lipides et procede d'utilisation
JPH09255698A (ja) * 1996-03-22 1997-09-30 Hankyu Kyoei Bussan Inc 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤
JP2002080496A (ja) 2000-09-04 2002-03-19 Univ Kyoto 新規な降圧ペプチド
WO2006052031A1 (en) 2004-11-15 2006-05-18 Mg Pharma Inc. Protein hydrolysate with antidiabetic effect

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
F. YOSHIHARA ET AL.: "Possible involvement of oxidative stress in hypoxia-induced adrenomedullin secretion in cultured rat cardiomyocytes", EUR J PHARMACOL, vol. 436, 2002, pages 1 - 6
IZUMIYA ET AL.: "Peptide Gosei", 1975, MARUZEN
SCHREDER; LUHKE: "The Peptide", vol. 1, 1966, ACADEMIC PRESS
See also references of EP2179740A4
T. HORIO ET AL.: "Gene expression and secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts", ENDOCRINOLOGY, vol. 144, 2003, pages 2279 - 2284
TOSHIRO MATSUI: "Production of Hypotensive Peptide, SVY, from 7S Globulin of Soybean Protein and Its Physiological Functions", SOYBEAN PROTEIN RESEARCH, vol. 6, 2003, pages 73 - 77
Y. TAKAMI ET AL.: "Diagnostic and prognostic value of plasma brain natriuretic peptide in non- dialysis-dependent chronic renal failure", AM J KIDNEY DIS, vol. 44, 2004, pages 419 - 429
YOSHIHARA ET AL.: "Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation. Plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure", J AM COLL CARDIOL, vol. 39, 2002, pages 288 - 294

Also Published As

Publication number Publication date
CA2695666A1 (en) 2009-02-12
JP5985028B2 (ja) 2016-09-06
JP2013116911A (ja) 2013-06-13
EP2179740B1 (en) 2014-10-08
KR20100051838A (ko) 2010-05-18
AU2008284709C1 (en) 2014-06-05
CN103251928B (zh) 2014-11-26
KR101244331B1 (ko) 2013-03-18
CN101815525A (zh) 2010-08-25
JP5850869B2 (ja) 2016-02-03
JP2013144696A (ja) 2013-07-25
EP2179740A1 (en) 2010-04-28
US20110166073A1 (en) 2011-07-07
CN101815525B (zh) 2013-05-29
AU2008284709A1 (en) 2009-02-12
EP2179740A4 (en) 2010-09-29
HK1187256A1 (en) 2014-04-04
HK1147210A1 (en) 2011-08-05
US8394769B2 (en) 2013-03-12
CA2695666C (en) 2016-05-17
JP2016026194A (ja) 2016-02-12
CN103251928A (zh) 2013-08-21
JPWO2009020189A1 (ja) 2010-11-04
JP5850870B2 (ja) 2016-02-03

Similar Documents

Publication Publication Date Title
NZ600690A (en) Fkbp-l and uses thereof
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
WO2006018652A3 (en) Antimicrobial peptides comprising an arginine- and/or lysine-containing motif
IN2014CN02050A (ja)
WO2009025117A1 (ja) Cdca1ペプチド及びこれを含む薬剤
WO2009025116A1 (ja) Cdh3ペプチド及びこれを含む薬剤
WO2004108938A3 (en) Peptide ligands of dendritic cells for nucleic acid vector targeting
WO2009004315A8 (en) Isolated peptides and uses thereof
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
WO2003020932A1 (en) Novel secretory proteins and dna thereof
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
WO2008113536A8 (en) Neurotrophic peptides
WO2009020189A1 (ja) 血圧降下剤
WO2008113970A3 (en) Peptides
WO2010057242A3 (de) Vakzin
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2008012689A3 (en) Cytokine derivatives
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
EP1842911A4 (en) HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
WO2011061720A3 (en) Viral citrullinated peptides and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880102397.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827111

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009526492

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008284709

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12671953

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2695666

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008827111

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008284709

Country of ref document: AU

Date of ref document: 20080807

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107004549

Country of ref document: KR

Kind code of ref document: A